Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 7
Submit an article Journal homepage
245
Views
0
CrossRef citations to date
0
Altmetric
Letter to the Editor

LenD: a study to establish the safety and efficacy of lenalidomide and dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia

Satyen Harish GohilDepartment of Academic Haematology, University College London Cancer Institute, London, UK; ;Department of Haematology, University College London Hospital, University College Hospital, London, UK; View further author information
,
Nicola MaciociaDepartment of Haematology, University College London Hospital, University College Hospital, London, UK; View further author information
,
Pip PatrickCRUK & UCL Cancer Trials Centre, London, UK; View further author information
,
Thomas RobertsCRUK & UCL Cancer Trials Centre, London, UK; View further author information
,
Nicholas CounsellCRUK & UCL Cancer Trials Centre, London, UK; View further author information
,
Paul SmithCRUK & UCL Cancer Trials Centre, London, UK; View further author information
,
Laura Clifton-HadleyCRUK & UCL Cancer Trials Centre, London, UK; View further author information
,
Kate CwynarskiDepartment of Haematology, University College London Hospital, University College Hospital, London, UK; View further author information
,
Andrew PettittNorth West Cancer Research Centre, University of Liverpool, Liverpool, UK; View further author information
&
Amit Chunilal NathwaniDepartment of Academic Haematology, University College London Cancer Institute, London, UK; ;Department of Haematology, University College London Hospital, University College Hospital, London, UK; ;National Health Services Blood and Transplant, Watford, Hertfordshire, UKCorrespondence[email protected]
View further author information
 show all
Pages 1730-1733 | Received 10 Jul 2017, Accepted 25 Oct 2017, Published online: 22 Nov 2017
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days
Click to increase image sizeClick to decrease image sizeFree first page

Acknowledgements

We are grateful for Celgene for funding the study and providing Lenalidomide free of charge, Cancer Research UK & UCL Cancer Trials Centre for overseeing the study and all staff & patients who participated.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article online at https://doi.org/10.1080/10428194.2017.1399311.

Additional information

Funding

This work was supported by the Celgene (RV-CLL-PI-0569).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.